0

    524636

    OXYGENTAPH

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    OXYGENTA PHARMACEUTICAL LIMITE Share Price Today

    Investment Returns

    Over 1 Month 5.73% Over 3 Months -11.64% Over 6 Months -13.74% Over 1 Year -52.94%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    OXYGENTA PHARMACEUTICAL LIMITE fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 188.30
    • P/E Ratio (TTM) -10.72
    • Beta 1.07
    • Book Value / share -11.54
    • Return on equity 0.00%
    • EPS (TTM) 0.00
    • Dividend yield [-]%
    • Net profit/quarter (Cr) -1.70
    info icon alternate text

    OXYGENTA PHARMACEUTICAL LIMITE Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 49.61
    Operating Expense 51.07
    Net Profit -1.70
    Net Profit Margin (%) -3.42
    Earnings Per Share (EPS) -0.45
    EBITDA 0.29
    Effective Tax Rate (%) -32.81
    Particulars DEC 2025 (Values in Cr)
    Revenue 33.93
    Operating Expense 40.26
    Net Profit -4.84
    Net Profit Margin (%) -14.26
    Earnings Per Share (EPS) -1.32
    EBITDA -4.08
    Effective Tax Rate (%) 23.38
    Particulars SEP 2025 (Values in Cr)
    Revenue 14.30
    Operating Expense 20.68
    Net Profit -4.93
    Net Profit Margin (%) -34.47
    Earnings Per Share (EPS) -1.33
    EBITDA -4.63
    Effective Tax Rate (%) 23.44
    Particulars JUN 2025 (Values in Cr)
    Revenue 15.13
    Operating Expense 23.43
    Net Profit -6.11
    Net Profit Margin (%) -40.38
    Earnings Per Share (EPS) -1.65
    EBITDA -6.67
    Effective Tax Rate (%) 25.03
    Particulars MAR 2025 (Values in Cr)
    Revenue 49.47
    Operating Expense 53.05
    Net Profit -2.15
    Net Profit Margin (%) -4.34
    Earnings Per Share (EPS) -0.60
    EBITDA -1.90
    Effective Tax Rate (%) 43.42
    Particulars MAR 2026 (Values in Cr)
    Revenue 112.98
    Operating Expense 135.45
    Net Profit -17.57
    Net Profit Margin (%) -15.55
    Earnings Per Share (EPS) -4.75
    EBITDA -15.07
    Effective Tax Rate (%) 20.78
    Particulars MAR 2025 (Values in Cr)
    Revenue 109.30
    Operating Expense 124.69
    Net Profit -10.30
    Net Profit Margin (%) -9.42
    Earnings Per Share (EPS) -2.86
    EBITDA -8.96
    Effective Tax Rate (%) 28.22
    Particulars MAR 2024 (Values in Cr)
    Revenue 39.64
    Operating Expense 53.59
    Net Profit -3.48
    Net Profit Margin (%) -8.77
    Earnings Per Share (EPS) -1.09
    EBITDA -9.62
    Effective Tax Rate (%) 74.90
    Particulars MAR 2023 (Values in Cr)
    Revenue 30.99
    Operating Expense 41.65
    Net Profit -11.57
    Net Profit Margin (%) -37.33
    Earnings Per Share (EPS) -6.36
    EBITDA -7.82
    Effective Tax Rate (%) -1.75
    Particulars MAR 2022 (Values in Cr)
    Revenue 60.52
    Operating Expense 61.56
    Net Profit -0.61
    Net Profit Margin (%) -1.00
    Earnings Per Share (EPS) -0.48
    EBITDA 2.02
    Effective Tax Rate (%) -24.48
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share -6.77
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin -7.97
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share -6.18
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin -24.27
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share -32.53
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin -25.27
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share -24.38
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 0.00
    EBITDA Margin 2.43
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share -37.27
    ROE % -5.79
    ROCE % 7.89
    Total Debt to Total Equity 0.00
    EBITDA Margin 7.55
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 0.12
    Total Assets 83.42
    Total Liabilities 83.42
    Total Equity -25.02
    Share Outstanding 3
    Price to Book Ratio -11.75
    Return on Assets (%) -11.60
    Return on Capital (%) -26.02
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 0.10
    Total Assets 63.19
    Total Liabilities 63.19
    Total Equity -20.12
    Share Outstanding 3
    Price to Book Ratio -4.69
    Return on Assets (%) -5.50
    Return on Capital (%) -9.38
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 0.10
    Total Assets 54.26
    Total Liabilities 54.26
    Total Equity -46.20
    Share Outstanding 1
    Price to Book Ratio -1.13
    Return on Assets (%) -21.32
    Return on Capital (%) -53.09
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.15
    Total Assets 31.17
    Total Liabilities 31.17
    Total Equity -34.62
    Share Outstanding 1
    Price to Book Ratio -0.99
    Return on Assets (%) -1.95
    Return on Capital (%) -3.49
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 0.44
    Total Assets 33.86
    Total Liabilities 33.86
    Total Equity -38.01
    Share Outstanding 1
    Price to Book Ratio 0.00
    Return on Assets (%) 8.65
    Return on Capital (%) 29.69
    Particulars MAR 2025 (Values in Cr)
    Net Income -11.55
    Cash from Operations 2.76
    Cash from Investing -11.24
    Cash from Financing 8.66
    Net change in Cash 0.02
    Free Cash Flow 14.15
    Particulars MAR 2024 (Values in Cr)
    Net Income -13.87
    Cash from Operations -13.04
    Cash from Investing -4.08
    Cash from Financing 17.13
    Net change in Cash 0.00
    Free Cash Flow -8.94
    Particulars MAR 2023 (Values in Cr)
    Net Income -11.37
    Cash from Operations -1.63
    Cash from Investing -9.63
    Cash from Financing 11.22
    Net change in Cash -0.04
    Free Cash Flow 8.01
    Particulars MAR 2022 (Values in Cr)
    Net Income -0.48
    Cash from Operations -1.55
    Cash from Investing -4.94
    Cash from Financing 6.33
    Net change in Cash -0.28
    Free Cash Flow 3.38
    Particulars MAR 2021 (Values in Cr)
    Net Income 3.14
    Cash from Operations -1.40
    Cash from Investing -6.71
    Cash from Financing 8.66
    Net change in Cash 0.32
    Free Cash Flow 5.33
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 32.45 13.46 1.57 248.68 23.12 38.85
    BLISS GVS PHARMA LTD 463.55 37.26 4.12 4916.24 118.35 552.90
    CIPLA LTD. 1410.90 31.85 3.31 113978.90 1165.55 1672.20
    FERMENTA BIOTECH LTD. 432.60 20.23 3.13 1273.18 256.40 480.00
    GLAXOSMITHKLINE PHARMA LT 2513.25 44.25 18.77 42575.97 2088.00 3217.10
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 32.45 22.69 4.18 248.68 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 510.50 22.88 3.98 1475.89 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8000.10 104.55 22.91 20000.25 7630.00 9850.00
    BLISS GVS PHARMA LTD 463.55 50.11 4.25 4916.24 118.35 552.90

    OXYGENTA PHARMACEUTICAL LIMITE shareholding pattern

    Holding
    43.43%
    56.53%
    0.02%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    OXYGENTA PHARMACEUTICAL LIMITE Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    50.91 5.51 redarrow
    red-green-graph indicator
    3 Bearish
    13 Bullish
    • 5 Days 49.50
    • 26 Days 49.00
    • 10 Days 49.20
    • 50 Days 49.80
    • 12 Days 49.10
    • 100 Days 52.00
    • 20 Days 49.00
    • 200 Days 57.10
    49.08 PIVOT
    First Support 47.17 First Resistance 50.15 Second Support 46.10 Second Resistance 52.06 Third Support 44.19 Third Resistance 53.13
    RSI 55.50 ADX 18.94 MACD 0.04 Williams % R -18.03 Commodity Channel Index (CCI) 141.02
    Date 2026-07-24 Week 5745.00 Same Day 15793.00 Month 5177.00
    1 Year 1.08 3 Year 0.78
    Over 1 Month
    5.73% down
    Over 1 Year
    -52.94% down
    Over 3 Months
    -11.64% down
    Over 3 Years
    9.25% down
    Over 6 Months
    -13.74% down
    Over 5 Years
    34.39% down

    OXYGENTA PHARMACEUTICAL LIMITE Corporate Actions

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Oxygenta Pharmaceutical Ltd?

    Answer Field

    Oxygenta Pharmaceutical Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 50.91 as on Jul 24 2026 03:29 PM.

    What is the Market Cap of Oxygenta Pharmaceutical Ltd Share?

    Answer Field

    The market cap of Oxygenta Pharmaceutical Ltd for NSE ₹ 0.00 & for BSE ₹ 188.30 as on Jul 24 2026 03:29 PM.

    What is the 52 Week High and Low of Oxygenta Pharmaceutical Ltd?

    Answer Field

    The 52 Week High and Low of Oxygenta Pharmaceutical Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 110.25 and ₹ 43.00.

    What is 1 year return for Oxygenta Pharmaceutical Ltd?

    Answer Field

    The 1 year returns on the stock has been -52.94%.

    What is the P/E Ratio of Oxygenta Pharmaceutical Ltd Share?

    Answer Field

    As on Jul 24 2026 03:29 PM the price-to-earnings (PE) ratio for Oxygenta Pharmaceutical Ltd share is -10.72.

    What is the PB ratio of Oxygenta Pharmaceutical Ltd Share?

    Answer Field

    As on Jul 24 2026 03:29 PM, the price-to-book (PB) ratio for Oxygenta Pharmaceutical Ltd share is -11.54.

    How to Buy Oxygenta Pharmaceutical Ltd Share?

    Answer Field

    You can trade in Oxygenta Pharmaceutical Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Oxygenta Pharmaceutical Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Oxygenta Pharmaceutical Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Oxygenta Pharmaceutical Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |